H Harder, L Nielsen, TDT Thi, A Astrup - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—After 8 weeks, liraglutide reduced fasting serum glucose (liraglutide, −1.90
mmol/l, and placebo, 0.27 mmol/l; P = 0.002) and HbA 1c (liraglutide, −0.33%, and placebo,
0.47%; P = 0.028) compared with placebo. No change in body weight was detected ( ... Cited by 90 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org S Madsbad, O Schmitz, J Ranstam, G Jakobsen, … - Diabetes Care, 2004 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A double-blind, randomized, parallel-group,
placebo-controlled trial with an open-label comparator arm was conducted among 193 outpatients
with type 2 diabetes. The mean age was 56.6 years and the mean HbA 1c was 7.6% ... Cited by 170 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org KB Degn, CB Juhl, J Sturis, G Jakobsen, B Brock, V … - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is potentially a very attractive agent for treating type 2
diabetes. We explored the effect of short-term (1 week) treatment with a GLP-1 derivative, liraglutide
(NN2211), on 24-h dynamics in glycemia and circulating free fatty acids, islet cell ... Cited by 170 - Related articles - BL Direct - All 8 versions
MN Feinglos, MF Saad, FX Pi-Sunyer, B An, O … - Diabetic …, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 65 - Related articles - BL Direct - All 5 versions
AM Chang, G Jakobsen, J Sturis, MJ Smith, CJ Bloem, … - Diabetes, 2003 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) stimulates insulin secretion in a glucose-dependent
manner, but its short half-life limits its therapeutic potential. We tested NN2211, a long-acting
GLP-1 derivative, in 10 subjects with type 2 diabetes (means ± SD: age 63 ± 8 years, BMI ... Cited by 94 - Related articles - BL Direct - All 9 versions
- ►pubget.com [PDF] H Agersø, LB Jensen, B Elbrønd, P Rolan, M … - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like peptide-1 (GLP-1), a polypeptide hormone secreted by the
l-cells in the gastrointestinal tract, has shown promising effects as a new treatment modality for
patients with Type II (non-insulin-dependent) diabetes mellitus. However, the ... Cited by 168 - Related articles - BL Direct - All 5 versions
[CITATION] NN2211-1310 International Study Group, et al. Improved glycemic control with no …
J Sturis, CF Gotfredsen, J Rømer, B Rolin, … - British journal of …, 2003 - pubmedcentral.nih.gov When liraglutide was dosed sc at 150 μg kg −1 bid for 6 weeks in ZDF rats 6–8 weeks of age
at study start, diabetes development was markedly attenuated. Blood glucose was approximately
12 mM lower compared to vehicle (P<0.0002), and plasma insulin was 2–3-fold higher ... Cited by 71 - Related articles - BL Direct - All 4 versions
KB Degn, B Brock, CB Juhl, CB Djurhuus, J Grubert, D … - Diabetes, 2004 - Am Diabetes Assoc This study assessed whether glucose-dependent insulin secretion and overall counterregulatory
response are preserved during hypoglycemia in the presence of exenatide. Twelve healthy fasted
volunteers were randomized in a triple-blind crossover study to receive either intravenous ... Cited by 124 - Related articles - BL Direct - All 6 versions
CB Juhl, M Hollingdal, J Sturis, G Jakobsen, H Agersø, … - Diabetes, 2002 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1) is a potent glucose-lowering agent of potential interest for the
treatment of type 2 diabetes. To evaluate actions of NN2211, a long-acting GLP-1 derivative,
we examined 11 patients with type 2 diabetes, age 59 ± 7 years (mean ± SD), BMI 28.9 ± ... Cited by 175 - Related articles - BL Direct - All 6 versions
